Invivoscribe Launches Automated Sample Prep Platform

PrepQuant System streamlines pre-analytical workflows for molecular testing

Apr. 15, 2026 at 5:05am

Got story updates? Submit your updates here. ›

A highly structured abstract painting in muted tones of blue, green, and gray, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conceptually representing the integrated automation and efficiency of the PrepQuant System's sample preparation workflow.The PrepQuant System's automated integration of nucleic acid extraction, concentration, and quantification aims to standardize pre-analytical workflows and improve the reliability of molecular diagnostics.San Diego Today

Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, has announced the launch of the PrepQuant System, a novel automated sample preparation platform that integrates nucleic acid extraction, concentration, and quantification into a single instrument. The system is designed to standardize sample prep and simplify pre-analytical workflows, reducing costs and eliminating a major source of inconsistency in molecular testing.

Why it matters

Reliable and consistent sample preparation is critical for precision diagnostics, especially in the era of liquid biopsy and MRD testing where the quality of starting material directly impacts test results. The PrepQuant System aims to address limitations of current automated instruments by consolidating multiple labor-intensive steps into a single platform, improving operational efficiency and reducing errors.

The details

The PrepQuant System was developed through a collaboration between Invivoscribe and Hitachi High-Tech Corporation. It is designed to be assay-agnostic, generating highly concentrated genomic DNA and cell-free DNA (cfDNA) for use in next-generation sequencing, qPCR, and digital PCR workflows. By automating extraction, concentration, and quantification, the system reduces variability and optimizes test results.

  • Invivoscribe will unveil the PrepQuant System at the AACR Annual Meeting in San Diego from April 19-22, 2026.
  • The company anticipates first commercial shipments in North America in August 2026, with European availability planned for January 2027.
  • New PrepQuant System kits expanding the menu are expected by the end of 2026.

The players

Invivoscribe

A global leader in precision diagnostics and measurable residual disease (MRD) testing.

Hitachi High-Tech Corporation

A company with proven technological and manufacturing capabilities in life science and clinical diagnostic instruments.

Jeff Miller

CEO and CSO of Invivoscribe.

Jordan Thornes

VP of Global Clinical Laboratory Operations at Invivoscribe.

Got photos? Submit your photos here. ›

What they’re saying

“The PrepQuant System represents a significant advancement in our commitment to standardize the entire testing process, starting with the pre-analytical workflow.”

— Jeff Miller, CEO and CSO of Invivoscribe

“Our teams recognized the limitations of currently available automated instruments, particularly the labor-intensive nature and increased risk of errors associated with running three separate protocols across multiple instruments. This all-in-one system was designed to reduce costs, while addressing those challenges and significantly improving operational efficiency.”

— Jordan Thornes, VP of Global Clinical Laboratory Operations

What’s next

Invivoscribe anticipates new PrepQuant System kit releases by the end of 2026, further expanding the menu and providing additional versatility across the spectrum of molecular testing.

The takeaway

The launch of the PrepQuant System demonstrates Invivoscribe's commitment to standardizing and streamlining the entire diagnostic testing process, from sample preparation to final results. By consolidating multiple steps into a single automated platform, the company aims to reduce variability, improve efficiency, and ensure the consistent, high-quality performance that is critical for precision medicine applications like liquid biopsy and MRD testing.